Income statement, balance sheet and cash flow statement for the last 6 fiscal years, taken from the XBRL data Definium Therapeutics, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Research and development
18.6
34.8
36.2
52.1
65.3
118
General and administrative
14.4
59.1
30.2
41.7
38.6
48.6
Operating expenses
33
93.9
66.3
93.9
104
166
Operating income
-33
-93.9
-66.3
-93.9
-104
-166
Interest expense
0.92
2.28
5.48
Interest income
5.58
11.6
11
Other non-operating income
-0.91
-0.34
9.54
-1.87
-4.76
-17.5
Pre-tax income
-33.9
-94.2
-56.8
-95.7
-109
-184
Income tax
-1.16
0
Net income
-33.9
-93
-56.8
-95.7
-109
-184
EPS, basic
-1.92
-3.40
-1.84
-2.44
-1.54
-2.06
EPS, diluted
-1.92
-3.40
-1.84
-2.44
-1.54
-2.06
Shares, basic (weighted)
18
27.4
30.9
39.2
70.5
89.3
Shares, diluted (weighted)
18
27.4
30.9
39.2
70.5
89.3
Balance sheet
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
80.1
134
142
99.7
274
258
Short-term investments
0
154
Other current assets
1.43
3.68
3.91
4.17
7.88
7.73
Total current assets
81.5
137
146
104
282
419
Goodwill
0
19.9
19.9
19.9
19.9
19.9
Intangible assets
6.87
3.69
0.53
0
Long-term investments
0
Other non-current assets
0.33
0.22
0.61
0.86
Total assets
81.5
164
170
125
302
440
Accounts payable
2.02
4.18
2.11
4.14
2.01
5.35
Accrued liabilities
0.99
6.23
5.88
11.6
12.8
20.4
Total current liabilities
3.01
10.4
17.9
32.2
38.8
66.7
Long-term debt
14.1
21.9
40.6
Other non-current liabilities
1.93
1.18
0.03
0.5
Total liabilities
5.65
12.3
19.1
46.4
60.7
108
Total debt
14.1
21.9
40.6
Paid-in capital
120
288
345
368
640
914
Retained earnings
-44.6
-138
-194
-290
-399
-583
Other comprehensive income
0.28
1.05
0.63
0.34
0.82
1.09
Shareholders' equity
75.9
152
151
78.1
241
332
Total equity
75.9
152
151
78.1
241
332
Total liabilities and equity
81.5
164
170
125
302
440
Shares outstanding
28.1
38
41.1
75.1
98.8
Cash flow statement
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-33.9
-93
-56.8
-95.7
-109
-184
Stock-based compensation
7.41
42.7
13.7
15.2
16.9
20.1
Deferred income tax
-1.16
Change in payables
0.54
1.28
-2.06
2.03
-2.13
3.34
Cash from operations
-23.6
-45.8
-50.1
-64.4
-79.1
-132
Acquisitions
-0.3
Purchases of investments
0
-268
Sales and maturities of investments
0
117
Cash from investing
-0.3
0
-152
Stock issued
72
81.9
42.3
7.53
0.98
0
Cash from financing
96.7
98.8
59.1
21.8
253
267
Net change in cash
73.4
53.4
8.6
-42.4
174
-15.9
Interest paid
0.53
2.22
5.34
Income taxes paid
0
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $36.17 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-38.5%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-31.8%
Net income / average total assets.
Return on invested capital (ROIC)
-59.9%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
Growth
Metric
Value
How it is calculated
Book value growth, 1y
37.6%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
30.1%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
34.4%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
45.7%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
37.3%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
40.1%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
26.8%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
42.5%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
37.8%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
6.95x
Current assets / current liabilities.
Quick ratio
6.89x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
6.89x
(Cash + short-term investments) / current liabilities.
Debt / equity
0.04x
Total debt / shareholders' equity. Not shown when equity is negative.
Debt / assets
3.3%
Total debt / total assets.
Liabilities / assets
17.5%
Total liabilities / total assets.
Net debt
-$1.05B
Total debt - cash - short-term investments. Negative means more cash than debt.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Operating cash flow per share
-$1.52
Cash from operations / diluted weighted shares.
Book value per share
$6.84
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/B
5.29x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
5.41x
Market cap / tangible book value, when positive.
Earnings yield
-7.3%
Net income / market cap (the inverse of P/E).
Was Definium Therapeutics, Inc. profitable in fiscal 2025?
No. It reported a net loss of $183.8M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.